N-acetylgalactosamine-functionalized Dendrimers As Hepatic Cancer Cell-targeted Carriers

Overview

Journal Biomaterials

Specialty Biomedical Engineering

Date 2011 Mar 25

PMID 21429574

Citations 20

Authors

Scott H Medina

Venkatesh Tekumalla

Maxim V Chevliakov

Donna S Shewach

William D Ensminger

Mohamed E H El-Sayed

Affiliations

Soon will be listed here.

Abstract

There is an urgent need for novel polymeric carriers that can selectively deliver a large dose of chemotherapeutic agents into hepatic cancer cells to achieve high therapeutic activity with minimal systemic side effects. PAMAM dendrimers are characterized by a unique branching architecture and a large number of chemical surface groups suitable for coupling of chemotherapeutic agents. In this article, we report the coupling of N-acetylgalactosamine (NAcGal) to generation 5 (G5) of poly(amidoamine) (PAMAM-NH₂) dendrimers via peptide and thiourea linkages to prepare NAcGal-targeted carriers used for targeted delivery of chemotherapeutic agents into hepatic cancer cells. We describe the uptake of NAcGal-targeted and non-targeted G5 dendrimers into hepatic cancer cells (HepG2) as a function of G5 concentration and incubation time. We examine the contribution of the asialoglycoprotein receptor (ASGPR) to the internalization of NAcGal-targeted dendrimers into hepatic cancer cells through a competitive inhibition assay. Our results show that uptake of NAcGal-targeted G5 dendrimers into hepatic cancer cells occurs via ASGPR-mediated endocytosis. Internalization of these targeted carriers increased with the increase in G5 concentration and incubation time following Michaelis-Menten kinetics characteristic of receptor-mediated endocytosis. These results collectively indicate that G5-NAcGal conjugates function as targeted carriers for selective delivery of chemotherapeutic agents into hepatic cancer cells.

Citing Articles

Nanotechnology for the Diagnosis and Treatment of Liver Cancer.

Cai Y, Wang W, Jiao Q, Hu T, Ren Y, Su X Int J Nanomedicine. 2024; 19:13805-13821.

PMID: 39735328 PMC: 11681781. DOI: 10.2147/IJN.S490661.

Hepatocyte targeting the asialoglycoprotein receptor.

Ramirez-Cortes F, Menova P RSC Med Chem. 2024; 16(2):525-544.

PMID: 39628900 PMC: 11609720. DOI: 10.1039/d4md00652f.

Targeting Breast Cancer with N-Acetyl-D-Glucosamine: Integrating Machine Learning and Cellular Assays for Promising Results.

Baysal O, Genc D, Silme R, Kirboga K, Coban D, Abdul Ghafoor N Anticancer Agents Med Chem. 2024; 24(5):334-347.

PMID: 38305389 DOI: 10.2174/0118715206270568231129054853.

Glycomimetics for the inhibition and modulation of lectins.

Leusmann S, Menova P, Shanin E, Titz A, Rademacher C Chem Soc Rev. 2023; 52(11):3663-3740.

PMID: 37232696 PMC: 10243309. DOI: 10.1039/d2cs00954d.

Nanoplatforms for Irinotecan Delivery Based on Mesoporous Silica Modified with a Natural Polysaccharide.

Brezoiu A, Prelipcean A, Lincu D, Deaconu M, Vasile E, Tatia R Materials (Basel). 2022; 15(19).

PMID: 36234345 PMC: 9571191. DOI: 10.3390/ma15197003.

References

Medina S, El-Sayed M . Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev. 2009; 109(7):3141-57. DOI: 10.1021/cr900174j. View

Tomalia D, Reyna L, Svenson S . Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans. 2007; 35(Pt 1):61-7. DOI: 10.1042/BST0350061. View

Kukowska-Latallo J, Candido K, Cao Z, Nigavekar S, Majoros I, Thomas T . Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005; 65(12):5317-24. DOI: 10.1158/0008-5472.CAN-04-3921. View

Schwartz A, Fridovich S, Lodish H . Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem. 1982; 257(8):4230-7. View

Svenson S, Tomalia D . Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev. 2005; 57(15):2106-29. DOI: 10.1016/j.addr.2005.09.018. View

Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Konishi J . Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J Magn Reson Imaging. 2001; 14(6):705-13. DOI: 10.1002/jmri.10025. View

Kitchens K, El-Sayed M, Ghandehari H . Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev. 2005; 57(15):2163-76. DOI: 10.1016/j.addr.2005.09.013. View

Sato N, Kobayashi H, Hiraga A, Saga T, Togashi K, Konishi J . Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med. 2001; 46(6):1169-73. DOI: 10.1002/mrm.1314. View

Seib F, Jones A, Duncan R . Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release. 2007; 117(3):291-300. DOI: 10.1016/j.jconrel.2006.10.020. View

10.

Gabellieri E, Strambini G, Shcharbin D, Klajnert B, Bryszewska M . Dendrimer-protein interactions studied by tryptophan room temperature phosphorescence. Biochim Biophys Acta. 2006; 1764(11):1750-6. DOI: 10.1016/j.bbapap.2006.09.008. View

11.

Zhou J, Wu J, Hafdi N, Behr J, Erbacher P, Peng L . PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb). 2006; (22):2362-4. DOI: 10.1039/b601381c. View

12.

Swanson S, Kukowska-Latallo J, Patri A, Chen C, Ge S, Cao Z . Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine. 2008; 3(2):201-10. PMC: 2527674. View

13.

Dong Q, Hurst D, Weinmann H, Chenevert T, Londy F, Prince M . Magnetic resonance angiography with gadomer-17. An animal study original investigation. Invest Radiol. 1998; 33(9):699-708. DOI: 10.1097/00004424-199809000-00026. View

14.

Seymour L, Ferry D, Anderson D, Hesslewood S, Julyan P, Poyner R . Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20(6):1668-76. DOI: 10.1200/JCO.2002.20.6.1668. View

15.

Hillaireau H, Couvreur P . Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009; 66(17):2873-96. PMC: 11115599. DOI: 10.1007/s00018-009-0053-z. View

16.

Zhong H, He Z, Li Z, Li G, Shen S, Li X . Studies on polyamidoamine dendrimers as efficient gene delivery vector. J Biomater Appl. 2007; 22(6):527-44. DOI: 10.1177/0885328207080005. View

17.

Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan R . Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials. 2005; 27(4):660-9. DOI: 10.1016/j.biomaterials.2005.06.007. View

18.

Backer M, Gaynutdinov T, Patel V, Bandyopadhyaya A, Thirumamagal B, Tjarks W . Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther. 2005; 4(9):1423-9. DOI: 10.1158/1535-7163.MCT-05-0161. View

19.

Liang H, Yang T, Huang C, Chen M, Sung H . Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release. 2005; 105(3):213-25. DOI: 10.1016/j.jconrel.2005.03.021. View

20.

David A, Kopeckova P, Rubinstein A, Kopecek J . Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem. 2001; 12(6):890-9. DOI: 10.1021/bc010026v. View